Irina Khlopotkina, Therapeutic area head (onco-2), Russia

Irina Sorokina, PhD, Global Medical Affairs Lead, Russia

Sergei Fogt, MD, PhD, Head of Early Clinical Development Unit, Russia

A BIOCAD’s History: The Inside Perspective
Irina Sorokina

Clinical development & registration of molecules — A challenge driven approach
Sergei Fogt

Aleksey Tryakin, MD, PhD, Professor, Deputy Director at the N.N. Blokhin National Medical Research Center of Oncology, Head of Oncology Department, Chairman of the groups for the development of clinical guidelines of the Russian Ministry of Health, dedicated to the treatment of cancer of the esophagus, colon and rectum, germ cell tumors. Member of the boards of the Russian Society of Clinical Oncology, Russia

Aleksey Tryakin, MD, PhD, Professor, Deputy Director at the N.N. Blokhin National Medical Research Center of Oncology, Head of Oncology Department, Chairman of the groups for the development of clinical guidelines of the Russian Ministry of Health, dedicated to the treatment of cancer of the esophagus, colon and rectum, germ cell tumors. Member of the boards of the Russian Society of Clinical Oncology, Russia

Lyudmila Zhukova, MD, PhD, Corresponding Member of the Russian Academy of Sciences, Deputy Director at the A. S. Loginov Moscow Clinical Scientific Center, Head of the Chemotherapy Department, Chairman of the groups for the development of clinical guidelines of the Russian Ministry of Health, dedicated to the treatment of breast cancer. Member of the boards of the Russian Society of Clinical Oncology, Russia

Ilya Timofeev, MD, PhD, Director of the Cancer Research Bureau, Member of the International Committee of ASCO (USA), Member of the Scientific Committee of the European School of Oncology (ESCO), Russia

10 Years of Confidence: Bevacizumab Biosimilar
Aleksey Tryakin
Blitz:Q&A Session

Confidence and Necessity: Advancing HER2+ Breast Cancer Care with Trastuzumab and Pertuzumab Biosimilars
Lyudmila Zhukova
Blitz:Q&A Session

Pembrolizumab biosimilar: the first you can trust
Ilya Timofeev
Blitz:Q&A Session

Daniil Stroyakovsky, MD, PhD, Head of the Chemotherapy Department, Moscow City Oncology Hospital No. 62, Moscow Healthcare Department, Member of the working group for the development of clinical guidelines of the Russian Ministry of Health on melanoma and lung cancer, Russia

Kristina Orlova, MD, PhD, Senior Research Fellow at the Department of Drug Therapy (Skin Tumors Division), Pediatric Oncologist at the N.N. Blokhin National Medical Research Center of Oncology, Member of the working group for the development of clinical guidelines of the Russian Ministry of Health on melanoma. Member of the boards of the professional association MelanomaPro, Russia

Daniil Stroyakovsky, MD, PhD, Head of the Chemotherapy Department, Moscow City Oncology Hospital No. 62, Moscow Healthcare Department, Member of the working group for the development of clinical guidelines of the Russian Ministry of Health on melanoma and lung cancer, Russia

Aleksey Tryakin, MD, PhD, Professor, Deputy Director at the N.N. Blokhin National Medical Research Center of Oncology, Head of Oncology Department, Chairman of the groups for the development of clinical guidelines of the Russian Ministry of Health, dedicated to the treatment of cancer of the esophagus, colon and rectum, germ cell tumors. Member of the boards of the Russian Society of Clinical Oncology, Russia

Elias Gracia, MD, Professor, Head of Medical Oncology Department at National Institute of Oncology and Radiobiology, Habana, Cuba

Prolgolimab: The Transformation from Wonder to Assurance
Kristina Orlova

Prolgolimab for patients with NSCLC: Domajor as a Symphony of Victory
Daniil Stroyakovsky

Prolgolimab in Neoadjuvant Therapy for Patients with CRC: Exceeding Expectations
Aleksey Tryakin

Immunotherapy with Prolgolimab and Pembrolizumab Biosimilar: Cuban expanded use program
Elias Gracia
Blitz:Q&A Session

Concluding Remarks and feedback
All participants

Kristina Orlova, MD, PhD, Senior Research Fellow at the Department of Drug Therapy (Skin Tumors Division), Pediatric Oncologist at the N.N. Blokhin National Medical Research Center of Oncology, Member of the working group for the development of clinical guidelines of the Russian Ministry of Health on melanoma. Member of the boards of the professional association MelanomaPro, Russia

Alexey Novik, D.Sc. in Medicine, Oncologist of the Department of Antitumor Drug Therapy, Oncologist of the Department of Organizational and Methodological Work with Regions, Senior Research Fellow of the Research Division for Cancer Immunology of the NMRC of Oncology named after N.N. Petrov of MoH of Russia, St. Petersburg

Fedor V. Moiseenko, D.Sc. in Medicine, Assoc. Prof., Head of the Department of Chemotherapy No. 1 at the N.P. Napalkov St. Petersburg Clinical Scientific and Practical Center for Specialized Medical Care (Oncology), Associate Professor of the Department of Oncology of the North-Western State Medical University named after I.I. Mechnikov, Senior Research Fellow of the Research Division for Innovative Techniques in Medical Oncology and Rehabilitation of the NMRC of Oncology named after N.N. Petrov of MoH of Russia, St. Petersburg

Svetlana Odintsova, D.Sc. in Medicine, Oncologist of the Department of Antitumor Drug Therapy, Oncologist of the Department of Organizational and Methodological Work with Regions, Senior Research Fellow of the Research Division for Cancer Immunology of the NMRC of Oncology named after N.N. Petrov of MoH of Russia, St. Petersburg

Opening remarks
Alexey V. Novik

From pilot trials to the birth of blockbusters in Russian immunotherapy
Alexey V. Novik

FORA — to be continued. Longer observation, stronger confidence in success!
Christina V. Orlova

Thriller with a Happy Ending: Key Findings from the DOMAJOR Study
Fedor V. Moiseenko

Forteca in NSCLC. Movie etude from real practice
Svetlana V. Odintsova

Lyudmila Zhukova, MD, PhD, Corresponding Member of the Russian Academy of Sciences, Deputy Director at the A. S. Loginov Moscow Clinical Scientific Center, Head of the Chemotherapy Department, Chairman of the groups for the development of clinical guidelines of the Russian Ministry of Health, dedicated to the treatment of breast cancer. Member of the boards of the Russian Society of Clinical Oncology, Russia

Sergei Fogt, MD, PhD, Head of Early Clinical Development Unit, Russia

Efficacy and safety of biosimilar pertuzumab in neoadjuvant therapy of HER2+ breast cancer. Results of the PREFER phase III clinical trial
Liudmila G. Zhukova

Evolution of neoadjuvant therapy for biologically aggressive subtypes of breast cancer: the role of biosimilars
Sergei N. Fogt